---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-245163"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2026-05-28T20:01:40+00:00"
generated_at: "2026-05-28T21:26:13.579112+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma enters new $1.8B unsecured revolver maturing 2031

## Summary
- New $1.8B unsecured revolving credit facility replaces existing agreement from 2021.
- Matures May 22, 2031; interest rate based on SOFR or base rate plus margin per pricing grid.
- Covenants: leverage ratio ≤4.00x (4.50x post-acquisition), portfolio cash flow ≤5.00x (5.50x), coverage ≥2.50x.
- Borrower: Royalty Pharma Holdings Ltd; guarantors: Royalty Pharma plc and Royalty Pharma Manager, LLC.

## SEC filing metadata
- accession: 0001193125-26-245163
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2026-05-28T20:01:40+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312526245163/0001193125-26-245163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312526245163/d131735d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-245163
- JSON: https://secwatch.observer/filing/0001193125-26-245163.json
- Plain text: https://secwatch.observer/filing/0001193125-26-245163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.